Arcadia Biosciences (RKDA) Accounts Payables (2014 - 2025)

Arcadia Biosciences' Accounts Payables history runs 12 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• Quarterly Accounts Payables fell 31.07% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 31.07% YoY) and the FY2025 annual result came in at $1.5 million, down 31.07% from the prior year.
• Accounts Payables was $1.5 million for Q4 2025 at Arcadia Biosciences, down from $2.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.2 million in Q2 2021 and bottomed at $905000.0 in Q4 2022.
• A 5-year average of $2.5 million and a median of $2.1 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables sank 65.63% — and 2023, when it surged 111.05%.
• Arcadia Biosciences' Accounts Payables stood at $1.4 million in 2021, then tumbled by 35.86% to $905000.0 in 2022, then soared by 111.05% to $1.9 million in 2023, then advanced by 10.37% to $2.1 million in 2024, then plunged by 31.07% to $1.5 million in 2025.
• Business Quant data shows RKDA's Accounts Payables at $1.5 million in Q4 2025, $2.0 million in Q3 2025, and $1.6 million in Q2 2025.